Osteoporosis drug may treat breast and liver cancers

February 19, 2014, Oregon State University

(Medical Xpress)—A drug used to prevent and treat osteoporosis in post-menopausal women may also be able to treat some breast and liver cancers, according to a new study from Oregon State University.

Although clinical trials on patients are still needed, in lab tests researchers found that the drug raloxifene, which is marketed under the brand name Evista by Eli Lilly and Co., killed human cells that are "triple-negative" as well as liver .

Triple-negative breast cancers represent about 15-20 percent of all breast cancers in the United States and are more common in younger and African-American women, according to a factsheet from the Susan G. Komen organization. Chemotherapy, radiation and surgery are the preferred treatments because triple-negative breast cancers don't respond to typical medications like tamoxifen or trastuzumab. That's because their cells lack receptors for estrogen, progesterone and a protein known as human epidermal growth factor receptor 2.

Receptors, which are proteins in or on cells, are like a lock. Hormones act like keys to these receptors to unlock different cellular functions. For example, estrogen causes uncontrolled proliferation of breast cancer cells by binding to a receptor. It's known that raloxifene blocks estrogen from binding to its receptor and thus keeps from multiplying.

But what OSU researchers discovered is that raloxifene also binds with a protein called the aryl hydrocarbon receptor (AhR) and kills cancer cells that do not have receptors for estrogen, said Ed O'Donnell, a postdoctoral scholar at OSU who conducted the research.

O'Donnell also analyzed survival data on women who had breast cancers that didn't require hormones to fuel the proliferation of the tumor cells. He found an increased survival rate in the women whose breast cancers had higher levels of the AhR protein.

"Our findings are exciting for two reasons," said OSU cancer researcher Siva Kolluri, who led the research, which was published in the journal Cell Death and Disease. "No. 1, our research revealed that we can target a specific protein, the AhR, to potentially develop new drugs for and a subset of stubborn breast cancers. That's a major goal of our lab. No. 2, we discovered that raloxifene, a known drug, could potentially be repurposed to treat two distinct types of cancers."

The U.S. Food and Drug Administration approved raloxifene for use in bone loss prevention in post-menopausal women in 1997. In 1999, it was approved for treating with osteoporosis. In 2007, the agency approved the use of raloxifene for reducing the risk of in post-menopausal women with osteoporosis and in post-menopausal women at high risk for invasive breast cancer, which spreads outside the lobules or milk ducts into surrounding breast tissue.

Raloxifene again hit the news in January when the federal government announced that most health insurance plans will be required to offer the prescription medicine at no cost to women who have an increased risk of developing breast cancer.

Explore further: Smoking linked with increased risk of most common type of breast cancer

More information: "The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells." O'Donnell EF, Koch DC, Bisson WH, Jang HS, Kolluri SK. Cell Death Dis. 2014 Jan 30;5:e1038. DOI: 10.1038/cddis.2013.549.

Related Stories

Smoking linked with increased risk of most common type of breast cancer

February 10, 2014
Young women who smoke and have been smoking a pack a day for a decade or more have a significantly increased risk of developing the most common type of breast cancer. That is the finding of an analysis published early online ...

Researchers discover new hormone receptors to target when treating breast cancer

February 4, 2014
According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs ...

Scientists link protein with breast cancer's spread to the brain

January 6, 2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.

USPSTF: Offer breast CA risk-reducing Rx to high-risk patients

September 24, 2013
(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends that women at increased risk of breast cancer be prescribed tamoxifen or raloxifene for risk reduction, according to a final Recommendation Statement ...

Additional drug shows promise for women with triple-negative breast cancer

December 13, 2013
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...

New finding points to potential options for attacking stem cells in triple-negative breast cancer

February 17, 2014
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.